A detailed history of Segall Bryant & Hamill, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 318,540 shares of NVO stock, worth $33.5 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares
318,540
Previous 224,618 41.81%
Holding current value
$33.5 Million
Previous $32.1 Million 18.3%
% of portfolio
0.53%
Previous 0.58%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$119.07 - $145.42 $11.2 Million - $13.7 Million
93,922 Added 41.81%
318,540 $37.9 Million
Q2 2024

Aug 14, 2024

SELL
$122.71 - $146.91 $2.79 Million - $3.34 Million
-22,735 Reduced 9.19%
224,618 $32.1 Million
Q1 2024

May 15, 2024

SELL
$102.11 - $135.92 $241,592 - $321,586
-2,366 Reduced 0.95%
247,353 $31.8 Million
Q4 2023

Feb 14, 2024

SELL
$87.78 - $105.45 $32 Million - $38.4 Million
-364,070 Reduced 59.32%
249,719 $25.8 Million
Q3 2023

Nov 09, 2023

BUY
$90.94 - $199.54 $25.7 Million - $56.3 Million
282,265 Added 85.14%
613,789 $55.8 Million
Q2 2023

Aug 11, 2023

BUY
$155.98 - $172.65 $808,600 - $895,017
5,184 Added 1.59%
331,524 $53.7 Million
Q1 2023

May 15, 2023

BUY
$132.34 - $159.14 $3.28 Million - $3.94 Million
24,784 Added 8.22%
326,340 $51.9 Million
Q4 2022

Feb 14, 2023

BUY
$102.55 - $135.33 $4.37 Million - $5.77 Million
42,660 Added 16.48%
301,556 $40.8 Million
Q3 2022

Nov 14, 2022

BUY
$95.28 - $116.93 $24.4 Million - $29.9 Million
256,071 Added 9064.46%
258,896 $25.7 Million
Q1 2022

May 13, 2022

BUY
$93.1 - $112.54 $263,007 - $317,925
2,825 New
2,825 $313,000
Q4 2021

Feb 14, 2022

SELL
$95.88 - $117.08 $278,531 - $340,117
-2,905 Closed
0 $0
Q3 2021

Nov 03, 2021

BUY
$84.42 - $106.62 $23,637 - $29,853
280 Added 10.67%
2,905 $278,000
Q2 2021

Aug 12, 2021

BUY
$67.66 - $84.76 $177,607 - $222,495
2,625 New
2,625 $219,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $238B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Segall Bryant & Hamill, LLC Portfolio

Follow Segall Bryant & Hamill, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.